Shin Nippon Biomedical Laboratories Valuation
Is YB3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of YB3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: YB3 (€9.55) is trading above our estimate of fair value (€6.29)
Significantly Below Fair Value: YB3 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for YB3?
Key metric: As YB3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is YB3's PE Ratio? | |
|---|---|
| PE Ratio | 16.6x |
| Earnings | JP¥3.90b |
| Market Cap | JP¥64.74b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.3x |
| Enterprise Value/EBITDA | 22x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does YB3's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 65.5x | ||
GXI Gerresheimer | 22.3x | 21.6% | €2.6b |
1SXP SCHOTT Pharma KGaA | 27.2x | 15.8% | €4.1b |
SRT3 Sartorius | 195.3x | 36.4% | €13.7b |
PSG PharmaSGP Holding | 17x | 13.9% | €309.3m |
YB3 Shin Nippon Biomedical Laboratories | 16.6x | 9.7% | €64.7b |
Price-To-Earnings vs Peers: YB3 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the peer average (65.5x).
Price to Earnings Ratio vs Industry
How does YB3's PE Ratio compare vs other companies in the European Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: YB3 is good value based on its Price-To-Earnings Ratio (16.6x) compared to the European Life Sciences industry average (36.7x).
Price to Earnings Ratio vs Fair Ratio
What is YB3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 16.6x |
| Fair PE Ratio | 12.4x |
Price-To-Earnings vs Fair Ratio: YB3 is expensive based on its Price-To-Earnings Ratio (16.6x) compared to the estimated Fair Price-To-Earnings Ratio (12.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.55
7D
2.0%
1Y
95.6%
Collegium Pharmaceutical
US$993.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.20
7D
5.0%
1Y
23.7%
Pharming Group
€478.2m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
1.8%
1Y
-31.2%